Syngeneic inoculated metastatic mammary cancers received direct intratumoral injection of a plasmid vector containing either endostatin (pEndo) with or without a suicide gene (pHSVtk), pHSVtk alone or control vector once a week for 8 weeks. We applied electrogene transfer to the tumors after each injection and administered ganciclovir (GCV) to pHSVtk-transfected mice using an osmotic minipump. Anticancer efficacy was monitored using a variety of parameters, namely tumor volume, intratumoral microvessel density and DNA synthesis, number of mice with metastasis, and number of sites of metastasis per mouse. Tumor volume was significantly lower in all therapeutic groups, with the most effective growth suppression in the pEndo þ pHSVtk/GCV group. Lymph node metastasis was significantly less frequent in all therapeutic groups, whereas the multiplicity of lung metastases was significantly lower only in the pEndo and pEndo þ pHSVtk/GCV groups. All therapeutic groups showed significantly lower intratumor microvessel density and DNA synthesis. The pEndo and pEndo þ pHSVtk/GCV groups also showed a significant reduction in the numbers of dilated lymphatic vessels containing intralumenal tumor cells. Our data suggest that endostatin electrogene therapy alone or in combination with pHSVtk/GCV suicide gene therapy is more beneficial than suicide gene therapy alone. The observed antimetastatic activity of endostatin may be of high clinical significance in the treatment of metastatic breast cancer.
Introduction
In Japan, the incidence of breast cancer is continuously increasing and the disease now ranks fifth as a cause of female subject mortality, the number of deaths rising 2.6-fold between 1975 and 1998. 1 In the United States, breast cancer is the second leading cause of cancer death in women, with approximately 200 000 American women diagnosed in 2002 and about 40 000 (20%) ultimately dying from the disease. 2 The lethality of breast cancer is largely the result of metastasis, the most common sites being lung, lymph nodes, liver and bone. Conventional cancer therapies used in breast cancer have yielded positive results; nevertheless, the rates for cure and survival remain unsatisfactory for a number of reasons, one being the difficulty in controlling and eradicating metastases without serious systemic side effects. Thus, there is a need for the development of more effective and less toxic therapies that can reduce morbidity and mortality.
Neovascularization is a key process in the growth of solid tumors, and they will not grow beyond a few cubic millimeters unless a vascular network is established to feed further expansion. 3 Growth of both primary tumors and metastases is thus angiogenesis dependent, and microvascular endothelial cells recruited by a tumor in the process of neovascularization have become an important second target of cancer therapy. 4 One promising, far-reaching strategy in gene therapy of neoplastic disease employs the concept of angiogenesis 5, 6 by transfecting genes encoding angiogenic inhibitors directly into the tumor itself. 4 Prevention of new vessel development within a growing tumor leads to an arrest in growth, and, in some cases, to regression. Many studies have shown that endostatin effectively checks the growth of primary tumors 6, 7 by interfering with the growth factor signaling necessary for endothelial cell proliferation, migration and vessel formation, thus inhibiting angiogenesis. [8] [9] [10] However, little is known about the possible antimetastatic actions of endostatin, particularly regarding mammary cancer metastasis.
Another approach to inhibit or halt neoplastic growth is to interrupt the cell cycle and/or induce apoptosis. When herpes simplex virus 1-thymidine kinase (HSVtk) is introduced into tumor cells, it can convert the nontoxic prodrug, ganciclovir (GCV), into a lethal DNA analog, which, when incorporated into DNA, leads to subsequent cell death by terminating DNA replication. 11 One key feature of this system is the 'bystander effect', by which complete tumor regression can occur after GCV administration even when only 10% of tumor cells have actually been transfected with HSVtk. 12 Many studies in various animal models have demonstrated that HSVtk/GCV treatment exerts antitumor effects in many types of cancer. 11 We have further shown that HSVtk/GCV therapy strongly suppresses metastasis in a murine metastatic mammary cancer model. 13 Gene transfer by in vivo electroporation (electrogene transfer) has recently been found to be an effective method for introducing DNA into various tissues. [14] [15] [16] [17] Although previously believed to have a very low transfection efficiency, it was recently reported that, under suitable conditions, transduction is approximately equivalent to that using an adenoviral vector concentration of 10 6 transduction U/ml. Although it was not as effective when compared to transfection using higher viral concentrations, 18 the technique offers some attractive advantages in that repeat transfections are possible for accumulation of gene transduction, as vector immunogenicity is generally not an issue; it is very easy to produce large-scale plasmids that can accommodate vectors with large DNA sizes; and the procedure has been demonstrated to be independent on cell cycling within target tissues. Experimental gene therapy using in vivo electroporation has, in fact, recently been demonstrated to effective in several animal tumor models, for colon adenocarcinomas, 19 melanomas, 20 hepatocellular carcinomas, 21 urinary bladder carcinomas 22 and mammary adenocarcinomas. 13, 23, 24 Here, we conducted an antiangiogenic gene therapy trial using electrogene transfer of endostatin in a mouse metastatic mammary cancer model having a metastatic spectrum similar to that seen in human breast cancers. As a paramount challenge for antiangiogenic therapy is to design combination protocols that counteract angiogenic stimuli produced by the tumor cells and induce direct/indirect cytotoxicity, we also tried combination gene therapy of endostatin and HSVtk/GCV using electrogene transfer.
Materials and methods

Vectors
The plasmids pBLAST-mEndo XVIII, which encodes murine endostatin in addition to the interleukin-2 (IL-2) signal sequence for secretion, and pGT60mcs, which encodes HSVtk, were obtained from InvivoGen Inc. (San Diego, CA). pBLAST-mEndo XVIII is regulated by the elongation factor-1a/human T cell leukemia virus type 1 long terminal repeat hybrid promoter; pGT60mcs is regulated by the CMV enhancer/promoter. For simplicity in this paper, these vectors are referred to as pEndo and pHSVtk, respectively. To produce the empty control vector (pVec), the HSVtk gene was deleted from pGT60mcs via digestion with SmaI/MluI. We chose the enhanced green fluorescence protein (eGFP), encoded within the pEGFP-N1 plasmid (Clontech Laboratories Inc., Palo Alto, CA), as a reporter gene for the in vitro study. All plasmid vectors were isolated from Escherichia coli (DH5a strain) and purified with a modified alkaline lysis procedure using a Qiagen Plasmid Maxi Kit (Qiagen Inc., Valencia, CA) and further purified with centrifugal filters (Ultrafree-MC, Millipore Co., Bedford, MA).
Cell lines and animals
Mouse mammary tumor virus, purified from medium in which Jyg-MC cells (established from mammary tumors of the Chinese wild mouse) were grown, was inoculated into the inguinal mammary glands of female BALB/c mice, resulting in the development of mammary carcinomas. 25 The BJMC3879 mammary adenocarcinoma cell line was subsequently derived from a metastatic focus within a lymph node from one of the inoculated mice and the cell line continues to show a high metastatic propensity, especially to lymph nodes and lungs. 13, 24, 26 We maintain the BJMC3879 line in Roswell Park Memorial Institute-1640 medium containing 10% fetal bovine serum supplemented with streptomycin/penicillin in an incubator under a 5% CO 2 atmosphere.
Primary isolated human umbilical vein endothelial cells (HUVECs; Cell Applications Inc., San Diego, CA) were cultured up to passage 9 at 371C with 5% CO 2 in modified endothelial growth medium (Cell Applications Inc.), supplemented with 4 ng/ml recombinant human vascular endothelial growth factor (rhVEGF; Sigma Co., St Louis, MO). Passages 3-9 were used for the cell proliferation studies and Matrigel assays.
A total of 24 6-week-old female BALB/c mice were used in this study (Japan SLC Inc., Hamamatsu, Japan). The animals were housed no more than six per plastic cage on wood chip bedding with free access to water and food and maintained under conditions of controlled temperature (21721C), humidity (50710%) and lighting (12-12 h light-dark cycle). All were held for a 1-week acclimatization period before test initiation; all manipulations and treatments of mice were performed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals at Osaka Medical College. At the termination of the study, all mice were euthanized under anesthesia.
In vitro vascular endothelial cell tubule formation on Matrigel To check the functional activity of angiostatic vectors, we examined in vitro HUVEC tubule formation. In the transfection process, HUVECs (1 Â 10 7 ) were suspended in 100 ml of HUVEC Nucleofector solution (amaxa GmbH, Ko¨ln, Germany) and 5 mg of either pEndo or pEGFP was added to the cell suspension. Electrogene transfer was then conducted using the amaxa Nucleofector program no. U01 appropriate for HUVECs. We then harvested the cells and plated them on 35-mm Matrigel dishes (Becton Dickinson, Bedford, MA) at a concentration of 1 Â 10 5 cells/plate. We supplemented the endothelial cell growth medium (Cell Applications Inc.) in the Matrigel plates with 4 ng/ml rhVEGF. The Matrigel contains essential basement membrane components (an extract of Engelbreth-Holm-Swarm murine tumor). After an 18-h incubation under 5% CO 2 , we aspirated the medium and rinsed the cultures with phosphatebuffered saline, fixed them in 10% phosphate-buffered formalin and performed gross evaluation of tube formation using a phase contrast microscope (model IX51; Olympus Optical Co., Tokyo, Japan) equipped with a digital camera (Polaroid Co., Cambridge, MA).
In vitro DNA synthesis and viability of transfected HUVECs and mammary carcinoma cells In the transfection process, HUVECs (1 Â 10 7 ) were suspended in 100 ml of HUVEC Nucleofector solution, whereas BJMC3879 cells (1 Â 10 7 ) were suspended in V solution (amaxa GmbH) in T-25 flasks and 5 mg of either pEndo or pEGFP was added to each cell suspension. We then conducted electrogene vector transfer using the amaxa Nucleofector with program no. U01 for HUVECs, as previously described, and program no. T03 for BJMC3879 cells. 24 The next day, the cells were harvested and seeded in 96-well optical bottom plates (10 4 cells/well). At 48-h posttransfection, cells from both cultures were incubated for 1 h in medium containing 50 mM 5-bromo-2'-deoxyuridine (BrdU), denatured with 1N HCl and exposed to an antiBrdU mouse monoclonal antibody (DakoCytomation, Carpinteria, CA). The cultures were then incubated with secondary antibody conjugated with horseradish peroxidase. Each well was then rinsed and covered with a luminol substrate (Roche Diagnostics GmbH, Renzberg, Germany) for 5 min. The light emission of the samples was measured using a luminometer (Luminoskan Ascent; Thermo Electron Co., Helsinki, Finland). The number of viable cells was counted 72 h after transfection using a hemocytometer with trypan blue exclusion.
In vivo pEndo and/or pHSVtk gene therapy BJMC3879 cells were inoculated into the right inguinal region of 24 female BALB/c mice. The animals were then randomly allocated to four groups of six mice each, namely the pEndo alone, pHSVtk alone, pEndo þ pHSVtk or pVec groups. Two weeks post-inoculation, when the tumors had reached 0.1-0.2 cm in diameter, we injected either pEndo alone, pHSVtk alone, pEndo þ pHSVtk or pVec directly into the tumors and then immediately performed in vivo electrogene transfer by applying a conductive gel (Aquasonic 100, Parker Lab. Inc., NJ) topically to the unshaved skin over the injected tumor. We used a vector concentration of 0.5 mg/ml saline; when using the combined vector treatment, 1.0 mg/ml each of the pEndo and pHSVtk vectors was mixed with the same volume to yield a final combined concentration of 0.5 mg/ml. The vectors were injected using a 27-gauge needle, whereas the animals were under avertin anesthesia. A total volume of 150 ml was introduced into larger tumors, whereas smaller tumors of 0.6-0.7 cm in diameter were infused until we detected leakage of the vector solution. Electric pulses were delivered directly to the tumor via 'forceps' platinum plate electrodes (CUY650-10; Nepa Gene Co., Ltd, Ichikawa, Japan) using a BTX T820 square-wave electropulser (BTX Inc., San Diego, CA). The conditions for electrogene transfer used in the present study were intratumoral injection of 50-75 mg plasmid (100-150 ml, dependent on tumor size as mentioned above) and eight pulses with a pulse length of 20 ms at 100 V/cm. The parameters for optimal electrogene transfer were determined previously. 13, 22, 24 Vector injection and electrogene transfer were performed once a week.
A 500 mg/10 ml saline solution of GCV (Denosin; Tanabe Pharmaceutical Co., Osaka, Japan) was prepared and dispensed continuously via Alzet mini-osmotic pumps (Alzet model 2002, Durect Co., Cupertino, CA) to animals receiving pHSVtk alone or combined pEndo þ pHSVtk therapy. The day after the first plasmid injection, the pumps were inserted subcutaneously into the back skin of pHSVtk and pEndo þ pHSVtk treated mice while under anesthesia. As the pumps were calibrated to release 0.5 ml solution/h (a calculated dosage of 30 mg/kg body weight) for 14 days, they were replaced every other week.
Using calipers, we measured the size of each treated mammary tumor weekly and calculated tumor volumes using the formula maximum diameter Â (minimum diameter) 2 Â 0.4. 27 Individual body weights were also recorded at weekly intervals. After 8 weeks of treatment, all mice received a single intraperitoneal (i.p.) injection of BrdU (Sigma); 1 h later, we euthanized the mice and removed the mammary tumors and certain lymph nodes (i.e., nodes from axillary and femoral regions as well as any that appeared abnormal). We then immediately fixed a portion of each tissue sample in 10% phosphatebuffered formalin and processed through to paraffin embedding; an additional portion of each tumor was also immediately frozen in liquid nitrogen for molecular analyses. Lungs were routinely inflated with the fixative, excised and immersed back in the fixative. We subsequently trimmed and examined all lobes for metastatic foci before processing through histology, where they were cut into 4-mm slices and stained with hematoxylin and eosin (H&E) for histopathological examination.
DNA synthesis in mammary tumors
As noted above, all animals received 100 mg/kg BrdU (Sigma) i.p. 1 h before killing and those mammary tumors selected from five animals from each treatment group were subsequently evaluated for DNA synthesis rates as inferred by BrdU incorporation. Using unstained paraffin-embedded tissue sections, tumor DNA was denatured by incubating the tissue in 4N HCl solution for 20 min at 371C and the incorporated BrdU was visualized after exposure to an anti-BrdU mouse monoclonal antibody (DakoCytomation). The number of S-phase cells incorporating BrdU into DNA per 1000-2000 cells was counted in five random high power fields ( Â 400) to give BrdU labeling indices as percentages of the total cells counted.
Apoptotic indices in mammary tumors
To quantitatively analyze apoptosis, we chose the terminal deoxynucleotidyl transferase-mediated dUTPdigoxigenin nick end-labeling (TUNEL) method with 4-mm sections from paraffin-embedded tumors and a fluorescein in situ apoptosis detection kit (ApopTag, Chemicon International, Temecula, CA) according to the manufacturer's protocol. The TUNEL/fluoresceinlabeled tissue sections were further stained with a 50 mg/ml propidium iodide (PI) solution and automatically scanned using a laser scanning cytometer (LSC2, Olympus) at Â 200 magnification. We expressed the number of TUNEL/fluorescein-positive cells as a percentage of the total number of PI-labeled viable cells counted. Sections of testes were employed as positive controls.
Lymphatic and blood microvascular density in mammary tumors
To quantitatively assess blood and lymphatic microvessel density in primary mammary carcinomas, we used the avidin-biotin immunohistochemical complex method (LSAB kit; DakoCytomation). A rabbit polyclonal antibody against the von Willebrand factor (vWF) (DakoCytomation), a specific marker for blood vessel endothelium, and a hamster monoclonal antibody antipodoplanin (AngioBio Co., Del Mar, CA), a lymphatic endothelium marker, were used. The numbers of immunopositive blood microvessels were counted according to methods outlined previously. 28 Briefly, the slides were scanned at low-power ( Â 100) magnification to identify those areas having the highest number of vessels; the five areas of highest microvascular density were then selected and counted at higher ( Â 200-400) magnification to obtain mean7s.d. values. In addition, the number of podoplanin-positive lymphatic vessels containing intralumenal tumor cells was also counted and expressed as the average7s.d.
Endostatin levels in mammary tumors
Total RNA was isolated from tumor tissues using an RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany) and cDNAs were synthesized with a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, GmbH, Mannheim, Germany) according to the manufacturer's protocol. cDNAs were amplified using a LightCycler quick system 330 (Roche Diagnostics) and a LightCyclerFastStart DNA Master SYBR Green I (Roche Diagnostics) according to the manufacturer's protocol. The primers for endostatin were 5 0 -CAACTCCTGTCTTG CATTGC-3 0 and 5 0 -ATCCTGCAGCCTAGAGGACA-3 0 , whereas those for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as an internal control, were The levels of endostatin mRNA were evaluated using a relative (to each GAPDH mRNA level) quantification method as previously described. 29 
Statistical analyses
Significant differences in the quantitative data between groups were analyzed using the Student's t-test via the method of Welch, which provides for insufficient homogeneity of variance. The differences in metastatic incidence were examined by Fisher's exact probability test, with Po0.05 or Po0.01 considered to represent a statistically significant difference.
Results
In vitro tubular formation of HUVECs transfected with endostatin As shown in Figure 1a and b, we found the in vitro transfection efficiency in HUVECs to be 90% or better as indicated by estimated GFP expression viewed under a fluorescence microscope. The addition of 4 ng/ml rhVEGF to the medium promoted the development of tubular structures by Matrigel-cultured, pEGFP-transfected HUVECs (Figure 1c ), but transfection with pEndo apparently inhibited tubule formation (Figure 1d ).
Cell viability and DNA synthesis in HUVEC and mammary carcinoma cultures transfected with endostatin Cell viability was significantly lower in both HUVEC and BJMC3879 cultures 48-h post-transfection with pEndo compared to corresponding pEGFP-transfected cells (Figure 1e ). DNA synthesis, evaluated by BrdU incorporation, was also significantly lower in both cell lines transfected with pEndo compared to the pEGFP-transfected cells (Figure 1f ).
Body weights and tumor growth in endostatin and/or HSVtk gene therapy No mortality was observed in this study. Reduction in body weight was not seen as a result of any treatment regimen and the general condition of all animals remained good throughout the experiment. The body weights at week 8 (the end of the study) were as follows: pVec group, 22.671.0 g; pEndo group, 22.871.4 g; pHSVtk/GCV, 23.070.8 g and pEndo þ pHSVtk/GCV group, 22.771.6 g. Data for tumor volumes are presented in Figure 2a . Tumor volumes in weeks 0-4 were magnified without s.d. values (Figure 2b ). Tumor volume increases were suppressed in the pEndo group, the pHSVtk/GCV group and the pEndo þ pHSVtk/GCV group from week 1. Compared to the pVec group, tumor volume in all treatment groups significantly decreased from week 2 to the end of the study. From week 3 on, tumor volume increases in the pEndo þ pHSVtk/GCV group began to decrease significantly compared with those in the pEndo alone and pHSVtk/GCV alone groups, the differences becoming even more pronounced as the study progressed. Tumor volumes were lowest in the pEndo þ pHSVtk/ GCV group compared to the groups transfected with pEndo or pHSVtk/GCV alone, significantly so at weeks 2-8. By weeks 7 and 8, the reduction in tumor volume increases in the pEndo þ pHSVtk/GCV group over the other treatment groups reached even greater significance.
Histopathology of endostatin-and HSVtk-treated mammary tumors Histopathologically, the implanted mammary carcinomas proved to be moderately differentiated adenocarcinomas. Tumor volume was significantly suppressed in mice transfected with pEndo only, pHSVtk/GCV only, or pEndo þ pHSVtk/GCV from week 1. Compared to the control group receiving pVec, tumor volume in all treatment groups was significantly lower from week 2 to the end of the study (*Po0.05; **Po0.01). From week 2 on, tumor volumes in the pEndo þ pHSVtk/GCV group began to decrease significantly compared to those in the pEndo alone and pHSVtk/GCV alone groups (wPo0.05; yPo0.01), the differences becoming even more pronounced (zPo0.05) by weeks 7 and 8. Data represent mean7s.d.
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Mammary tumors were characterized by some degree of central necrosis and inflammatory reaction independent of treatment ( Figure 3a ). Tumors transfected with pEndo only typically presented with island-like areas of viable tissue within necrotic regions (Figure 3b ), whereas lesions from the pHSVtk /GCV group exhibited massive necrotic areas with inflammatory cell infiltration (Figure 3c ). Macrophage accumulation was also detected in the peripheral and necrotic regions in the tumors of this group (Figure3c, inset) , a finding in line with our previous in vivo electroporation studies. 13, 22 Mammary tumors receiving pEndo þ pHSVtk/GCV showed a mixed phenotype incorporating features of both the pEndo alone and pHSVtk/GCV alone groups (Figure 3d ).
Metastasis in endostatin-and HSVtk-transfected mice
Metastases to lymph nodes. All control mice (100%) treated with pVec-developed metastases to the lymph nodes (Figure 3e ), whereas the incidence dropped to 50% in pEndo only (Figure 3f ), pHSVtk/GCV and pEndo þ pHSVtk/GCV groups. In addition, the overall number of lymph node metastases per mouse was significantly lower in the pEndo, pHSVtk/GCV and pEndo þ pHSVtk/GCV groups compared to the control mice (Figure 4a ).
Metastases to lungs.
In contrast to the lymph nodes, we saw no impact on the incidence of lung metastasis; regardless of treatment, lung metastasis occurred in almost 100% of the mice in all groups. However, qualitatively, metastatic lung nodules tended to be smaller in size in both the pEndo and pEndo þ pHSVtk/GCV groups (Figure 3h , j) compared to the pVec control group (Figure 3g ). Metastatic lung nodules in the pHSVtk/GCV group also showed more variation in size and numbers present per lobe (Figure 3i ). Quantitative measurements of the numbers of the metastatic lung nodules (p1 mm) per mouse confirmed the significant inhibition of metastases upon exposure to both pEndo alone and pEndo þ pHSVtk/GCV (Figure 4b ), but no significant difference was found in the numbers of metastatic lung foci between mice receiving empty vector and those transfected with pHSVtk/GCV (Figure 4b) because of large variations in number.
Metastases to other organs. Mammary carcinomas treated with pVec showed a wide spectrum of metastases to other organs, including liver, kidney, ovary and the adrenals. Other than the lymph nodes and lungs, distantsite metastasis was apparently limited to the liver upon HSVtk/GCV treatment. In contrast, exposure to pEndo and pEndo þ pHSVtk/GCV prevented any spread of metastasis beyond the lymph nodes and lungs. When we determined the total number of all metastases to any organ by treatment group, an overall decrease was found in multiplicity for all three therapeutic groups compared to the pVec control (Figure 4c) . We also noted that the overall number of organs with metastases per mouse was significantly lower in the pEndo and pEndo þ pHSVtk/ GCV groups compared to the control ( Figure 4d) ; Figure 3 Histopathological analysis of both transfected primary mammary tumors and pulmonary and lymphatic metastases. Independent of treatment, the mammary carcinomas induced by BJMC3879 cell inoculation proved to be moderately differentiated adenocarcinomas (a), accompanied by central necrosis (asterisk) and some inflammation. In some areas, mammary tumors treated with pEndo showed a characteristic feature of islands of viable tumor cells surrounded by necrotic tissue (b). Massive cell death was observed in pHSVtk/GCV-transfected tumors (c); macrophage accumulation (inset, c) was frequently seen in the peripheral zones of necrotic regions in these tumors. Mixtures of both features were observed in tumors transfected with pEndo þ pHSVtk/GCV (d), and included influxes of macrophages (inset, d). Metastasis to lymph nodes occurred frequently in all mice treated with pVec (e); the lymphoid sinuses were filled with mammary carcinoma cells (arrows)(inset). A lymph node from a mouse treated with pEndo shows no metastasis (f). Lymph node metastasis dropped to less than 50% in mice whose tumors were transfected with pEndo, pHSVtk/GCV or pEndo þ pHSVtk/GCV. Metastatic foci/nodules of the lungs from a mouse transfected with pVec (g), with pEndo (h), with pHSVtk/GCV (i) and with pEndo þ pHSVtk /GCV (j); note the differences in size and multiplicity of metastatic foci between the pVec and therapeutic groups. (Original magnification: H&E, a-d, Â 100, bar ¼ 100 mm; inset in cue, Â 400, bar ¼ 50 mm; e-j, Â 40, bar ¼ 250 mm).
treatment with pHSVtk/GCV alone also produced a decrease, but it was not statistically significant (Figure 4d) .
DNA synthesis and cell death in treated mammary tumors
The levels of DNA synthesis in each group, as inferred from the BrdU labeling indices, are illustrated in Figure 4e . DNA synthesis was significantly lower in all therapeutic groups compared to the pVec group. The number of TUNEL-positive cells was significantly greater, indicating increased cell death, in tumors transfected with pEndo, pHSVtk or pEndo þ pHSVtk/GCV, compared to those transfected with empty vector (Figure 4f ). There were no significant differences in DNA synthesis and cell death among the pEndo, pHSVtk/GCV and pEndo þ pHSVtk/GCV groups.
Blood and lymphatic microvessel density in treated mammary tumors Microvessel density, as determined by immunohistochemical analysis with the blood vessel endothelial cell marker vWF (Figure 5a-d) , was significantly lower in all groups given therapeutic regimens compared to the control group, the most pronounced reduction occurring with exposure to pEndo þ pHSVtk/GCV (Table 1 ). There was no significant difference in microvascular density among the treatment groups, although there appeared to be an additive trend downward in that the density in pVec tumors4pEndo tumors4pHSVtk/GCV tumors4 pEndo þ pHSVtk/GCV tumors.
The lymphatic microvessels in mammary tumors were stained with anti-podoplanin antibody, as demonstrated in Figure 5e and f. Independent of treatment, these vessels were well developed in the outer, superficial layers of the mammary tumors in a somewhat hexagonal network pattern (Figure 5e ). We frequently found tumor cells within the lumina of dilated lymphatic vessels of tumors in both control and treated animals (Figure 5f ). However, as summarized in Table 1 , the number of vessels with intralumenal tumor cells was significantly lower in lesions transfected with pEndo alone or pEndo þ pHSVtk/GCV. The number of migrating tumor cells was also significantly lower in the lymphatics of tumors transfected with pEndo alone or pEndo þ pHSVtk/GCV compared to the pVec group. As with blood microvascular density, pEndo þ pHSVtk/GCV therapy appeared to be more effective than transfection with either pEndo or pHSVtk alone.
Endostatin levels in mammary tumors
Relative endostatin levels in mammary tumors were higher in the pEndo and pEndo þ pHSVtk/GCV groups ( Figure 6 ). However, as endostatin levels showed large variation, they did not differ significantly. Nevertheless, mammary tumors transfected with endostatin showed 20-to 40-fold higher endostatin levels than the pVec control group.
Discussion
Human breast cancers metastasize mainly to the lymph nodes, lungs, liver and bone, and widespread and Figure 4 Quantitative analysis of metastasis in mice treated with pEndo7pHSVtk/GCV. (a) The number of lymph nodes with metastases per mouse was significantly lower in animals receiving pEndo alone (*Po0.05), pHSVtk/GCV alone (*Po0.05) and pEndo þ pHSVtk/GCV (**Po0.01). (b) The number of lung metastases was similarly significantly lower in mice transfected with pEndo alone (*Po0.05) or with pEndo þ pHSVtk/GCV (*Po0.05); the reduction seen in animals receiving pHSVtk/GCV only was not statistically significant from the control values. (c) The relative reduction in the total number of organs with any amount of metastasis seen in all therapeutically treated groups was not significant when compared to the control mice. (d) However, a significant reduction in the number of organs per mouse with any metastasis was detected in the pEndo alone (*Po0.05) and in the pEndo þ pHSVtk/GCV groups (*Po0.05); decreases were also noted in mice given pHSVtk/GCV only, but, owing to large variations, they did not achieve statistical significance. Data represent the mean7s.d. Quantitative analyses of DNA synthesis (e) and cell death (f) detected in mammary tumors treated with pEndo7pHSVtk/ GCV gene therapy. (e) BrdU labeling indices, indicative of DNA synthesis levels, derived for transfected tumors were significantly lower in mice treated with pEndo, pHSVtk/GCV and pEndo þ pHSVtk/GCV compared with those treated with pVec-transfected. (f) The number of TUNEL-positive cells was significantly higher in mice treated with pEndo, pHSVtk/GCV and pEndo þ pHSVtk/GCV compared with pVec, indicating an increase in intratumor cell death. Data represent mean7s.d.; *Po0.05; **Po0.01 compared with the pVec controls.
Combination gene therapy with endostatin and suicide genes M-A Shibata et al intractable metastasis leads to death. In fact, Carter et al. 30 have reported that tumor size and nodal status are practical parameters for estimating disease prognosis. In addition, once breast cancers reach 4 cm or larger, the chance of tumor recurrence and/or metastasis increases dramatically. 30 Therefore, treatments that offer suppression of both tumor growth and metastasis have significant clinical implications.
Endostatin is a 20-kDa C-terminal fragment of collagen XVIII that has been shown to inhibit endothelial cell proliferation and tumor angiogenesis by several mechanisms, including blocking the binding of VEGF 121 and VEGF 165 to the kinase insert domain protein receptor (KDR)/Flk-1 (fetal liver kinase-1) receptor, which mediates endothelial cell motility and proliferation; blocking phosphorylation of the tyrosine receptor; and blocking activation of the intracellular signaling kinases ERK (extracellular signal-regulated kinase), p38 MAPK (mitogen-activated protein kinases) and p125 FAK (focal adhesion kinase). 8, 31 Endostatin gene transfer has resulted in significant tumor growth arrest in various cancers in laboratory animals. 6, 7 We have been able to demonstrate that, at least in the mouse mammary cancer model used here, in vivo electrogene transfer of endostatin does suppress tumor growth and in particular metastasis without systemic toxicity. In the present study, we found clear suppression of angiogenesis and primary growth, and, to a lesser extent, metastasis, in tumors transfected with pEndo and pHSVtk/GCV, accompanied by a reduction in tumor DNA synthesis and increased cell death induction. We achieved statistically significant tumor growth inhibition using pEndo þ pHSVtk gene therapy with systemic GCV administration. However, we were unable to show a synergistic effect on suppression of overall metastasis with the combination regimen.
Systemic endostatin protein therapy was previously shown to suppress tumor-induced angiogenesis and tumor growth 8 when used in a regimen of daily injections of large amounts of recombinant protein. Conversely, a separate investigation found endostatin to be much more effective when administered by continuous injection of a lower dose compared to daily subcutaneous injections of higher doses. 32 A few Phase I clinical trials with recombinant endostatin have also been conducted and, although no obvious toxicity was reported, there was no clear clinical benefit evident. 33 The trial investigators proposed two major reasons for endostatin's apparent inefficacy: (i) as endostatin dosages were derived from extrapolation of data from animal experiments, the dosages may have been inappropriate for human patients and (ii) continuous infusion may be more advantageous than a single daily infusion, supporting the previous study. 32 In fact, pharmacokinetic data now show that endostatin has a circulatory half-life of only B12.9 h. 34 One of the major advantages of gene transfer is the quicker achievement of a steady-state level of circulating protein compared with conventional cyclical administration of recombinant proteins. Gene therapy may thus be advantageous as a means of systemic delivery of protein drugs, especially in situations where long-term production and secretion from a conveniently transduced tissue can be effected.
Phase I/II clinical trials of HSVtk/GCV therapy have indicated that some patients may achieve complete or partial clinical remission of their tumors. [35] [36] [37] HSVtk/ GCV therapy specifically targets cell division processes. The GCV is converted to the monophosphate form by HSVtk, which is further phosphorylated by endogenous mammalian kinase into GCV triphosphate, which is incorporated into replicating DNA, inhibiting DNA polymerase and leading to cell death. In addition, HSKtk/GCV therapy has also been shown to induce mitochondria-mediated apoptosis. 22 HSVtk/GCV therapy has the additional advantage of eliciting a 'bystander effect', in which neighboring untransfected tumor cells become susceptible to GCV killing after HSVtk treatment. Whereas HSVtk/GCV therapy does suppress transplanted murine mammary carcinoma in immunocompetent syngeneic mice, the efficacy is decreased in athymic nude mice that do not have an intact T-cell system, suggesting that T-cell-mediated immune responses may be a crucial factor for the bystander phenomenon. 38, 39 The cytokine IL-12 plays an important role in the induction of a T-cell-mediated immune response. 40 Produced primarily by macrophages and/or dendritic cells, it functions in enhancing the activity of cytotoxic T cells and inducing their production of interferon (IFN)g. 41 In addition, IFNg augments the immune response by activating macrophages and by increasing antigen-presenting capability. In the present study, macrophage accumulation was characteristically observed in tissues peripheral to central necrosis in mammary tumors treated with pHSVtk/GCV and pEndo þ pHSVtk/GCV, and as both genes induced antiangiogenesis, a combination effect in immune response and angiostasis might be expected in the pEndo þ pHSVtk/GCV group.
Experimental combination therapy with endostatin has exhibited some successful synergistic effects on primary tumor growth, [42] [43] [44] correlating with the results of our study. However, the present experimental models did not focus on any antimetastatic effects that might have been evident. Although there was a trend towards reduction, the combined pEndo þ pHSVtk/GCV therapy used in the present study did not exert a significant synergistic effect on inhibition of metastasis to organs other than the lungs and lymph nodes. As endostatin inhibited DNA synthesis of tumor cells both in vitro and in vivo, it is possible that HSVtk/GCV therapy, which specifically targets cells actively replicating DNA, may not have had a sufficient cell population on which to exert a strong effect when used in combination with endostatin gene. In addition, the timing of initiation of GCV administration may be crucial; a delay may be necessary in order to allow optimal endostatin expression after vector transfer, before killing the co-transfected cells by GCV treatment. In the present study, but as a mini-osmotic pump was used for continuous GCV administration to the animals, the timing of initiation of flash GCV administration should be considered.
Cancer cells metastasize to distal sites via the lymphatic system as well as through the vascular system. The lymphatic capillaries present in tissues and tumors provide entrance into the lymphatics, allowing cancer cell migration to the lymph nodes. VEGF-C expression has been shown to correlate with lymph node metastasis in a variety of human cancers, including breast neoplasms, 45, 46 and the cognate VEGF-C receptor, VEGFR-3, is predominantly expressed on lymphatic endothelial cells. 47 In vivo HSVtk/GCV electrogene therapy has previously been shown to suppress metastasis of mouse mammary carcinoma. 13, 48 In addition, electrogene transfer of endostatin was recently reported to inhibit B16 melanoma lung metastasis. 49 In the present study, we found a significant decrease in microvessel density in the pEndo, pHSVtk/GCV and pEndo þ pHSVtk/GCV groups. In addition, we also observed a significant decrease in the number of lymphatic vessels with tumor cells in their Number of lymphatic vessels with migrating cancer cells was determined as described in Materials and methods. Figure 6 Relative levels of endostatin mRNA showed a tendency to increase in the pEndo and pEndo þ pHSVtk/GCV groups, but this was not statistically significant. Mammary tumors from three mice in each group were examined. Data represent mean7s.d.
lumina in the pEndo alone and pEndo þ pHSVtk/GCV groups, compared to the pVec control group, indicating an inhibitory effect on migration. Endostatin, with or without HSVtk/GCV, may affect the capacity for cancer cell migration by interfering with VEGF-C/VEGFR-3 binding or expression within lymphatic vessels, but further investigation is needed in this area. Nonetheless, as endostatin directly acts on cancer cells, that is, decreases survival and DNA synthesis of mammary cancer cells in vitro and in vivo, this situation may lead to inhibition of cancer migration to blood and lymphatic vessels. Therefore, it is possible that endostatin can suppress both lymphatic and hematogeneous metastases. Further investigation is necessary to elucidate this point.
In conclusion, we have demonstrated that endostatin therapy (or with adjuvant HSVtk/GCV) suppresses tumor growth and significantly reduces metastasis to both lymph nodes and lungs in a mouse mammary cancer model. The total number of all distant-site metastases involving the lymph nodes and lungs was significantly lower in all therapeutic groups. However, a significant synergistic antimetastatic effect was not found with pEndo þ pHSVtk/GCV combination therapy compared to the pEndo group. We believe the antimetastatic activity of endostatin to be of high clinical significance for the treatment of metastatic human breast cancer.
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